HD256.05 cl1

General

Cell Line

hPSCreg name CSSi004-A
Cite as:
CSSi004-A (RRID:CVCL_VD31)
Alternative name(s)
HD256.05 cl1
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
RCi004-A-1
(RCi004-A + HTT GC #H34-32_T34-23)
Donor's gene variants:
HTT
Donor diseases:
Huntington disease
RCi004-A
(PDSC-10, RCi150)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
RCi004-B
(RCi68, PDSC-3)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi002-A
(#2c3, CHDI-90002150)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi006-A
(#6c7, CHDI-90002154)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi008-A
(#8c3, CHDI-90002156)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi011-A
(#11c2, CHDI-90002159)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi017-A
(#17c1, CHDI-90002165)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi018-A
(#18c1, CHDI-90002166)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi019-A
(#19c9, CHDI-90002167)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi021-A
(#21c5, CHDI-90002169)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi028-A
(#28c3, CHDI-90002176)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi035-A
(#108c5, CHDI-90002183)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi036-A
(#110c5, CHDI-90002184)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi038-A
(#112c7, CHDI-90002186)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi040-A
(#115c6, CHDI-90002188)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi045-A
(#121c6, CHDI-90002193)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi046-A
(#122c1, CHDI-90002194)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
RGIe098-A
(SI-194)
Donor diseases:
Huntington disease
CHDIi001-A
(#1c8, CHDI-90002149)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi003-A
(#3c1, CHDI-90002151)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi005-A
(#5c4, CHDI-90002153)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi010-A
(#10c2, CHDI-90002158)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi020-A
(#20c2, CHDI-90002168)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi022-A
(#22c1, CHDI-90002170)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
IIMCBi006-B
(M-T2)
Donor diseases:
Huntington's Disease
CHDIi026-A
(#26c3, CHDI-90002174)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
KCLe009-A
(KCL012_HD3)
Donor diseases:
Huntington disease
CHDIi029-A
(#29c4, CHDI-90002177)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
KCLe010-A
(KCL013_HD4)
Donor diseases:
Huntington disease
CHDIi031-A
(#31c1, CHDI-90002179)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi033-A
(#104c2, CHDI-90002181)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi034-A
(#105c1, CHDI-90002182)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi041-A
(#116c2, CHDI-90002189)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
ICGi033-B
(77Q-9)
Donor diseases:
Huntington disease
CHDIi048-A
(#125c2, CHDI-90002196)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
ICGi033-C
(77Q-20)
Donor diseases:
Huntington disease
CHDIi049-A
(#127c2, CHDI-90002197)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi055-A
(#133c5, CHDI-90002203)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
VUBe005-A
(VUB05_HD)
Donor diseases:
Huntington disease
GENEAe013-A
(GENEA089)
Donor diseases:
Huntington disease
GENEAe015-A
(GENEA020)
Donor diseases:
Huntington disease
GENEAe018-A
(GENEA090)
Donor diseases:
Huntington disease
GENEAe019-A
(GENEA091)
Donor diseases:
Huntington disease
IIMCBi006-A
(M-T1)
Donor diseases:
Huntington's Disease
INSRMe003-A
(STR-I-155-HD)
Donor diseases:
Huntington disease
RGIe091-A
(SI-186)
Donor diseases:
Huntington disease
RGIe092-A
(SI-187)
Donor diseases:
Huntington disease
ICGi033-A
(77Q-17)
Donor diseases:
Huntington disease
Last update 17th October 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Fondazione Casa Sollievo della Sofferenza IRCCS (CSS)
Owner Fondazione Casa Sollievo della Sofferenza IRCCS (CSS)
Distributors
Derivation country Italy

External Databases

BioSamples SAMEA104622926
Cellosaurus CVCL_VD31
Wikidata Q54814682

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 25-29
Ethnicity caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation.
Stage
Pre-symptomatic
Synonyms
  • Huntington chorea

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
Karyotyping method: G-Banding

External Databases (Donor)

BioSamples SAMEA104622927

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Confirm that consent was obtained by a qualified professional Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Modelling in vitro di patologie genetiche rare e neurodegenerative: generazione di iPS e loro differenziamento a partire da cellule somatiche del paziente
Does consent permit unforeseen future research, without further consent? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent expressly permit collection of genetic information? Yes
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Casa Sollievo della Sofferenza Ethics Commettee
Approval number 75/CE
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Casa Sollievo della Sofferenza Ethics Commettee
Approval number 75/CE
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Addgene

hIPSC Derivation

General

Source cell type
Age of donor (at collection) 25-29
Collected in 2017

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
Yes
Methods used
RT-PCR
Files and images showing reprogramming vector expressed or silenced
Vector map

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Morphology, marker expression, teratoma formation
Derived under xeno-free conditions
Yes
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Mechanically
CO2 Concentration 5 %
Medium Other medium:
Base medium: Nutristem XF (Biological Industries)
Main protein source:
Serum concentration: %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro directed differentiation
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
In vitro spontaneous differentiation
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
In vitro spontaneous differentiation

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Karyogram
Karyotyping method: G-Banding

Other Genotyping (Cell Line)